CorVista wins FDA clearance for AI heart failure assessment add-on
July 29, 2026
CorVista’s AI-based pulmonary capillary wedge pressure add-on test represents the third FDA clearance for its cardiopulmonary platform.
CorVista’s AI-based pulmonary capillary wedge pressure add-on test represents the third FDA clearance for its cardiopulmonary platform.
Saber-C AVIA is a zero-profile construct providing biomechanical stability similar to that of traditional plate systems.
Smith+Nephew (NYSE:SNN) announced today that the FDA granted de novo clearance for its TESSA spatial surgery system.